03/11/2015 - 12:50pm

Mylan expanded its portfolio of generic products with the U.S. launch of buprenorphine hydrochloride sublingual tablets in 2-mg and 8-mg strengths, the generic version of Subutex from Reckitt Benckiser.

03/11/2015 - 12:40pm

Mylan on Wednesday announced the launch of disulfiram tablets USP in dosage strengths of 250 mg and 500 mg.

03/11/2015 - 12:27pm

Mylan launched its fentanyl transdermal system in 37.5-, 62.5- and 87.50-mcg/hr dosage strengths in the United States.

03/10/2015 - 1:19pm

Actavis expanded its portfolio of topicals with the launch of a generic corticosteroid.

03/06/2015 - 11:37am

The Food and Drug Administration approved Zarxio, making it the first approved biosimilar product in the United States.

03/04/2015 - 6:28pm

While the big four analgesic manufacturers — Bayer, Pfizer, McNeil and Novartis — command the lion’s share of retail ad support behind their mega analgesic brands, Prestige Brands and BedRock Brands are making headway promoting their niche pain relieving products.

03/04/2015 - 6:28pm

Almost half of all circular ads in support of a digestive remedy promote an antacid tablet. 

03/04/2015 - 6:28pm

According to ECRM’s analysis of circular retail promotions for allergy, Chattem emerged as the leading advertiser of allergy remedies.

03/04/2015 - 6:28pm

Chattem’s launch of the first nasal corticosteroid onto OTC shelves represented the most significant success story in the cough-cold-allergy space in the past year.